Epic Sciences, Inc., a San Diego, CA-based biotech company that designs and develops novel diagnostics to personalize and advance the treatment and management of cancer, completed a $30m Series C financing.
Backers included new investors RusnanoMedInvest (RMI) and Arcus Ventures, existing investors Domain Associates, Roche Venture Fund, and Pfizer Venture Investments, as well as undisclosed individual investors.
The company intends to use the funds to commercialize its circulating rare cell analysis platform with special focus on developing products and services to detect circulating tumor cells (CTC) in cancer.
Led by Murali Prahalad, Ph.D., president and CEO, and co-founder Dr. Peter Kuhn, professor of Biological Sciences at the University of Southern California, Epic has developed technology that enables the minimally invasive characterization of protein biomarker and genomic profiles in CTCs allowing for therapy selection and the early drug resistance detection.
Epic is developing diagnostic tests to quantify the proteomic and genomic changes that occur over time during the treatment of a patient’s cancer, from a minimally invasive liquid biopsy. For clinical and pharma partners, the company provides a report that can incorporate CTC enumeration, quantitative protein biomarker analysis and single-cell genomic analysis by next generation sequencing (NGS) or fluorescent in situ hybridization (FISH). The information provided by the report can be used to monitor and personalize cancer treatments at every clinical decision point.
Epic’s technology was exclusively licensed from the Kuhn Lab at The Scripps Research Institute.